BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF 2-(4-ETHOXYPHENYL SULPHONAMIDO) PENTANE-DIAMIDE, A NOVEL ANTITUMOR AND ANTIANGIOGENIC AGENT, IN RAT SERUM AND APPLICATION OF THE METHOD IN DETERMINATION OF PHARMACOKINETIC PARAMETERS

NILUFA YEASMIN; SUVASISH MISHRA; KOUSHIK SARKER; SUBRATA SEN

doi:10.22159/ijap.2024v16i1.49426

Authors

NILUFA YEASMIN Biju Patnaik University of Technology, Rourkela, Odisha,India https://orcid.org/0009-0005-3425-0205
SUVASISH MISHRA College of Pharmaceutical Sciences, Mohuda, Berhampur, Odisha-760002, India https://orcid.org/0000-0001-5738-6299
KOUSHIK SARKER College of Pharmaceutical Sciences, Mohuda, Berhampur, Odisha-760002, India
SUBRATA SEN College of Pharmaceutical Sciences, Mohuda, Berhampur, Odisha-760002, India

DOI:

https://doi.org/10.22159/ijap.2024v16i1.49426

Keywords:

LC-MS, Validation, Pharmacokinetic study, Bioavailability, PK-solver

Abstract

Objective: The present study focuses on the development and validation of a bioanalytical method for the quantification of 2-(4-ethoxyphenyl sulphamido) pentane-diamide, a candidate antitumor and antiangiogenic agent, in rat serum. The developed method was subsequently applied to determine the pharmacokinetic parameters of the compound.

Methods: To quantify the compound and determine its pharmacokinetic properties in rats, a liquid chromatography-mass spectrometry (LC-MS) bioanalytical method has been developed and the pharmacokinetic parameters were computed by compartmental model analysis.

Results: A linear relationship was detected within the concentration range of 10 to 5000 ng/ml prepared by adding standard solutions of the test compound to the pooled serum of 10 SD rats, which exhibits high levels of precision, accuracy, and reproducibility. An appreciable recovery in the range of 97.20±0.63 to 93.22±1.48 percent was determined, with no noticeable impact from the matrix. The pharmacokinetic parameters, namely oral absorption rate constant (Ka) (5.054±0.238 1/h), elimination rate constant (KE) (2.585±0.357 h), volume of distribution (V) (8.173±0.333 L/kg), and bioavailability of (73.2%), were determined by the utilization of PK-solver software.

Conclusion: We developed a simple yet precise and validated LC-MS method to analyze the drug candidate in rat serum. Simple protein precipitation and extraction were cost-effective. This bioanalytical approach was successful due to its good linearity, high recoveries, no matrix influence, and matrix stability. PK solver derived I. V. and oral pharmacokinetics parameters from the best-fit one-compartment model. Because of its high oral absorption, biological half-life, and bioavailability, the compound is suitable for oral administration.

Downloads

Download data is not yet available.

References

Saha A, Sarker K, Ghosh A, Mishra S, Sen S. Rational design, synthesis and in vitro evaluation of n-(4-ethoxyphenylsulfonyl)-l-glutamic acid analogues as antiangiogenic and anticancer agents on multiple myeloma. Indian Drugs. 2021;57(12):26-35. doi: 10.53879/id.57.12.12807.

Gallo JM. Pharmacokinetic/ pharmacodynamic-driven drug development. Mt Sinai J Med. 2010 Jul-Aug;77(4):381-8. doi: 10.1002/msj.20193, PMID 20687184.

Singh J, Elbarbry F, Lan K, Grabowski T. Animal pharmacokinetic/pharmacodynamic studies (APPS) reporting guidelines. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):483-94. doi: 10.1007/s13318-018-0498-2, PMID 30117069.

Tiwari G, Tiwari R. Bioanalytical method validation: an updated review. Pharm Methods. 2010 Oct;1(1):25-38. doi: 10.4103/2229-4708.72226, PMID 23781413.

Tan A, Awaiye K. Use of internal standards in LC-MS bioanalysis, Handbook of LC-MS bioanalysis: best practices, experimental protocols, and regulations. 1st ed. John Wiley & Sons, Inc; 2013.

Bioanalytical method validation-guidance for industry, U. S. Department of Health and Human Services, Food and Drug Administration, Center For Drug Evaluation And Research (CDER), Center For Veterinary Medicine (CVM). Biopharmaceutics. 2018. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

Crutchfield CA, Marzinke MA. Bioanalytical development and validation of liquid chromatographic-tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood. Pract Lab Med. 2015 Mar 14;1:12-21. doi: 10.1016/j.plabm.2015.03.003, PMID 28932794.

Moein MM, El Beqqali A, Abdel Rehim M. Bioanalytical method development and validation: critical concepts and strategies. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Feb 1;1043:3-11. doi: 10.1016/j.jchromb.2016.09.028, PMID 27720355.

Fisher EN, Melnikov ES, Gegeckori V, Potoldykova NV, Enikeev DV, Pavlenko KA. Development and validation of an LC-MS/MS method for simultaneous determination of short peptide-based drugs in human blood plasma. Molecules. 2022 Nov 14;27(22):7831. doi: 10.3390/molecules27227831, PMID 36431933.

Li R, Fan H, Gu Y. Determination of Boc5 in rat plasma by HPLC–MS/MS and its application to a pharmacokinetic study. Chromatographia. 2012;75:721. doi: 10.1007/s10337-012-2248-y.

Leng G, Zuo Y, Hu J, Yu F, Liu W. Liquid chromatography tandem mass spectrometry method for determination of fulvestrant in rat plasma and its application to pharmacokinetic studies of a novel fulvestrant microcrystal. Biomed Chromatogr. 2020 Oct;34(10):e4912. doi: 10.1002/bmc.4912, PMID 32496589.

Zhang, Yang Xm Xl, Chen Yc. LC method for determination of ginkgolic acids in mice plasma and its application to a pharmacokinetic study. Chroma. 2009;69:593-6. doi: 10.1365/s10337-008-0903-0.

Das D, Halder D, Bose A, Shaw TK, Saha C, De PK. Determination of metformin and sitagliptin in healthy human volunteers’ blood plasma and its bioequivalence study under fasting condition. Int J Appl Pharm. 2022;14(6):42-50. doi: 10.22159/ijap.2022v14i6.45140.

Gurav P, Damle M. Bioanalytical method for estimation of teriflunomidein human plasma. Int J Pharm Pharm Sci. 2022;14(9):19-23. doi: 10.22159/ijpps.2022v14i9.45151.

Alumuri T, Merugu K, Amarababu NLA, Kurnool A. Peramivir and related impurities in rat plasma and its applications in pharmacokinetic studies (Bioanalytical method development and validation by LC-MS/MS). Int J Appl Pharm. 2022;14(5):53-61. doi: 10.22159/ijap.2022v14i5.45457.

Inturi R, Raju MD, Basaveswara Rao MV, Inturi S. Pharmacokinetic investigation of remogliflozin in rat plasma samples by high-throughput HPLC-MS-MS. Int J Appl Pharm. 2022;14(6):178-85. doi: 10.22159/ijap.2022v14i6.45700.

Putriana NA, Rusdiana T, Rostinawati T, Akbar MR, Nurfuadah I. Validation of warfarin analysis method in human blood plasma using high-performance liquid chromatography with fluorescence detection. Int J App Pharm. 2022;14(5):132-8. doi: 10.22159/ijap.2022.v14s5.27.

Chen Y, Gao X, Gupta R, Ma J, Dere R, Liang D. Development and validation of an LC-MS/MS method for AC1LPSZG and pharmacokinetics application in rats. J Chromatogr Sci. 2022 Jan 1;60(1):26-34. doi: 10.1093/chromsci/bmab020, PMID 33667297.

Kunati SR, Xu Y. Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC-MS/MS. Biomed Chromatogr. 2017 Mar;31(3). doi: 10.1002/bmc.3818, PMID 27554984.

Zhou W, Yang S, Wang PG. Matrix effects and application of matrix effect factor. Bioanalysis. 2017 Dec;9(23):1839-44. doi: 10.4155/bio-2017-0214, PMID 29171768.

Rajagopaludu P, Saritha N, Devanna N, Srinivas M. Method development and validation of erythromycin and olaparib in human plasma by liquid chromatography–tandem mass spectrometry. Asian J Pharm Clin Res. 2022;15(4):28-33. doi: 10.22159/ajpcr.2022v15i4.44044.

Munshi R, Jv V. Reverse phase high-performance liquid chromatography-ultraviolet-based approach for method development and validation of lacosamide estimation in human serum. Asian J Pharm Clin Res. 2022;15(11):98-102. doi: 10.22159/ajpcr.2022.v15i11.45501.

Mastanamma SK, Satya AT, Tejaswi J, Chiranmai M, Hema K. Separation and identification of forced degradation products of lofexidine by using LC-MS/MS. Asian J Pharm Clin Res. 2022;15(9):210-22. doi: 10.22159/ajpcr.2022v15i9.45117.

Nandi U, Dan S, Pal TK. Development and validation of a liquid chromatography–mass spectrometry method for simultaneous determination of metoprolol and telmisartan in rat plasma and its application to pharmacokinetic study. J Pharm Investig. 2015;45(3):329-40. doi: 10.1007/s40005-015-0180-5.

De S, Dey S, Shah S. Simultaneous determination of atorvastatin and atenolol in rabbit plasma by RP-HPLC method and its application in pharmacokinetic study. Int J Curr Pharm Res. 2022;14(2):72-8.

Buyya SS, Mittal A. Bio-analytical method development and validation for simultaneous determination of ledipasvir and sofosbuvir drugs in human plasma by RP-HPLC method. Int J Curr Pharm Res. 2018;10(3):21-6. doi: 10.22159/ijcpr.2018v10i3.27223.

Romero Castro A, Gutierrez Sanchez M, Correa Basurto J, Rosales Hernandez MC, Padilla Martinez II, Mendieta Wejebe JE. Pharmacokinetics in wistar rats of 5-[(4-Carboxybutanoyl)amino]-2-hydroxybenzoic acid: a novel synthetic derivative of 5-aminosalicylic acid (5-ASA) with possible anti-inflammatory activity. PLOS ONE. 2016 Jul 25;11(7):e0159889. doi: 10.1371/journal.pone.0159889, PMID 27454774.

Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010 Sep;99(3):306-14. doi: 10.1016/j.cmpb.2010.01.007, PMID 20176408.